about
Azathioprine and UVA light generate mutagenic oxidative DNA damagePharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapyStructure and dynamics of thioguanine-modified duplex DNAA disease spectrum for ITPA variation: advances in biochemical and clinical researchBiomarkers in cancer staging, prognosis and treatment selectionAnticancer agent shikonin is an incompetent inducer of cancer drug resistanceVariants of a Thermus aquaticus DNA polymerase with increased selectivity for applications in allele- and methylation-specific amplification.Molecularly evolved thymidylate synthase inhibits 5-fluorodeoxyuridine toxicity in human hematopoietic cellsABCB1 genetic variants in leukemias: current insights into treatment outcomesClinical implementation of germ line cancer pharmacogenetic variants during the next-generation sequencing era.Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients.Pharmacogenetics and folate metabolism -- a promising direction.Direct observation and quantitative characterization of singlet oxygen in aqueous solution upon UVA excitation of 6-thioguanines.Microarrays in pharmacogenomics--advances and future promise.The emergence of resistance to targeted cancer therapeutics.The impact of pharmacogenomics on gastrointestinal cancer therapy.Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care.Host genetics in follicular lymphomaReport from the fifth National Cancer Institute Mouse Models of Human Cancers Consortium Nervous System Tumors Workshop.Germline genetic variation and treatment response on CCG-1891.Quantification of Thiopurine/UVA-Induced Singlet Oxygen ProductionTechnical reproducibility of single-nucleotide and size-based DNA biomarker assessment using DNA extracted from formalin-fixed, paraffin-embedded tissues.Pharmacogenetic candidate genes for melanoma.Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.Pharmacogenetics and inflammatory bowel disease: progress and prospects.Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).Ancestry and pharmacogenetics of antileukemic drug toxicityPharmacogenomics of adverse effects of anti-leukemic agents in children.Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism.Pharmacogenetics of folate-related drug targets in cancer treatment.Folate during antifolate chemotherapy: what we know... and do not know.Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.The role of drug-metabolising enzymes in clinical responses to chemotherapy.Should pharmacogenomic studies be required for new drug approval?Pharmacogenetics of acute lymphoblastic leukemia treatment response.Genetic variations in stem cell-related genes and colorectal cancer prognosisPharmacogenetics in acute lymphoblastic leukemia.Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer.Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.
P2860
Q24657288-BAC5CF22-7867-4D77-BCAC-7CBACAFF3FBDQ24676890-AACEE4DE-23EF-4404-A1AF-5707CCD8F77DQ27639874-0AD37378-3E5B-4A76-BFBD-BB79E7EF7412Q28069352-3369E761-0E4E-4E47-A7F1-4BC5BC99C55DQ28278305-E18ACBE5-9DD6-497D-B687-5B2CA9BAF463Q28484828-4452049F-0B39-43ED-8641-366A6F38BC81Q33573008-C2201621-644D-4E05-A19A-8E19BD38DAA2Q33691845-949D4E13-F0EC-4ED0-9B2A-BA33FEC96B10Q33707782-7C8AA7B1-335D-40E3-A292-BB8B46BFE501Q34026161-245B83F5-2ED6-4000-AD39-D9E39202508DQ34129436-CA60F203-0F4B-4053-B4F7-6D9DC5DAFF66Q34673321-BE93AC0A-3BE1-47BB-B071-B907B06A248EQ34815465-BE92EAD4-6B32-4B95-8372-3A73D8F2E35DQ34836984-FA1CB698-0B97-4079-B357-FB9E003E00A7Q34837015-7AECA940-C3B4-4456-BB3F-407B54A6F917Q34837030-103B9BCE-18BF-4AD8-A22C-FA586DACF17AQ35016589-B01AFCD0-E922-4A55-AF89-9ADE60771524Q35038312-0EB2B1C6-BE76-4905-B5DE-A2888E820EA5Q35085344-AAABFD2F-A42E-40C8-B460-9B5A2C97F611Q35190653-C688DD01-95C1-479C-BF73-3814FEE9BCA6Q35534821-1AA5938C-BA08-49F4-8EAF-862B814228A0Q35543090-DC0AFAF5-ED9A-4D4E-B4B8-568F85595AFCQ35574952-6AF88514-D160-4608-9A0D-04B1B6148753Q35772582-00C5F24D-4170-4150-98A0-10522F7A1DD2Q35787609-F8F371F3-36A3-4CCF-9CB3-4EE953886378Q35797649-8C0CC2B0-833A-457C-BC76-38045B18C436Q35828717-04ACBB6B-9D79-4420-85D5-77AAA46FDE92Q36191097-0C982C26-A775-49C4-A96E-C51D75755F40Q36218993-0C3539B3-0E96-4295-B3F6-54EA3AC1A165Q36248267-22ED9360-3DF0-4B1D-AC11-490F1670AABAQ36278007-1EA3F7C4-0A49-432D-8A3D-8C713055D521Q36278412-619EAAB2-60E4-4FFA-9D66-17891A2B5F85Q36402208-E5D11F40-017D-4FA7-B825-B9E7B7A77ED8Q36545015-9298A85F-747A-4F87-8304-BD0AF9A331B0Q36752667-D3A7424E-C22A-481E-B782-80453482BD35Q36968156-864C1D9E-FBC2-4DF5-BA9A-2D82D65B6610Q37040950-DA8DA524-C280-4D19-A0AE-F0069130B0E8Q37150913-4059845F-07C0-44BE-9A8B-F6C6258775B5Q37158252-92E94D98-8E6A-4419-9A19-C82FAA0378DCQ37163352-7F24C4DA-BB1E-4A96-B3CF-F65EE8D0AC16
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacogenetics and cancer therapy.
@ast
Pharmacogenetics and cancer therapy.
@en
Pharmacogenetics and cancer therapy.
@nl
type
label
Pharmacogenetics and cancer therapy.
@ast
Pharmacogenetics and cancer therapy.
@en
Pharmacogenetics and cancer therapy.
@nl
prefLabel
Pharmacogenetics and cancer therapy.
@ast
Pharmacogenetics and cancer therapy.
@en
Pharmacogenetics and cancer therapy.
@nl
P356
P1476
Pharmacogenetics and cancer therapy.
@en
P2093
Dervieux T
Relling MV
P2888
P304
P356
10.1038/35101056
P407
P577
2001-11-01T00:00:00Z
P5875
P6179
1050167536